Quarterly results round-up: Qiagen suffers from international unrest, while TrueBeam drives healthy Varian growth
This article was originally published in Clinica
Executive Summary
Dutch molecular diagnostics firm Qiagen has blamed a drop in first-quarter net sales on the earthquakes in Japan and New Zealand and political unrest in North Africa. The firm posted Q1 revenues of $264.3m, largely unchanged over the same period last year, but down 2% on a constant currency basis.